Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Hedgehog-signalling cooperates with PI3K-signalling during transformation of the mammary gland
EF 2017-18
Résumé
This study investigates molecular mechanisms involved in the transformation of the mammary gland, or breast, using a mouse model possessing a recessive mutation in the Patched-1 (Ptch1) gene. Patched-1 is a transmembrane receptor protein required for repression of Smoothened (Smo) activity in the Hedgehog (Hh)-signalling pathway, a fundamental developmental pathway. Dysregulation of this pathway has been implicated in a number of cancers, including breast cancer.We have determined that this mutation in Ptch1 prevents the development of the mammary gland in mice during puberty, without interruption of 'canonical' Hh-signalling through Smo. Therefore, this suggests 'non-canonical' Hh-signalling, operating independent of Smo, is crucial for normal mammary gland development. Interestingly, in mice with this mutation the effects of potent oncogenes, such as ErbB2 and c-src, are altered. Collectively, our studies suggest the presence of a novel network of interacting molecules, involving Ptch1, are imperative for normal breast development. Thus, I hypothesize that a 'non-canonical' Hh-pathway involving Ptch1, in cooperation with interacting molecules, affects the ability of p110-alpha, a gene found mutated in numerous human breast cancers, to produce tumours.To address this hypothesis, transgenic mice with mutations in the pathways controlled by Ptch-1 and p110-alpha, the Hh and PI3K pathways, respectively, coupled with molecular-genetic in-vitro experiments, will be used to observe how these pathways interact to cause breast cancer. Taken together, these studies will provide insight into a novel interaction between two 'druggable' pathways (Hh and PI3K), and how these two pathways cooperate to produce breast cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386436
Name
Gjelaj Ersa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Hedgehog-signalling cooperates with PI3K-signalling during transformation of the mammary gland
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Developmental Pathway; Hh-Pathway; Mammary Gland; Patched-1; Pi3k-Pathway; Transgenic Mice
Abstract
This study investigates molecular mechanisms involved in the transformation of the mammary gland, or breast, using a mouse model possessing a recessive mutation in the Patched-1 (Ptch1) gene. Patched-1 is a transmembrane receptor protein required for repression of Smoothened (Smo) activity in the Hedgehog (Hh)-signalling pathway, a fundamental developmental pathway. Dysregulation of this pathway has been implicated in a number of cancers, including breast cancer.We have determined that this mutation in Ptch1 prevents the development of the mammary gland in mice during puberty, without interruption of 'canonical' Hh-signalling through Smo. Therefore, this suggests 'non-canonical' Hh-signalling, operating independent of Smo, is crucial for normal mammary gland development. Interestingly, in mice with this mutation the effects of potent oncogenes, such as ErbB2 and c-src, are altered. Collectively, our studies suggest the presence of a novel network of interacting molecules, involving Ptch1, are imperative for normal breast development. Thus, I hypothesize that a 'non-canonical' Hh-pathway involving Ptch1, in cooperation with interacting molecules, affects the ability of p110-alpha, a gene found mutated in numerous human breast cancers, to produce tumours.To address this hypothesis, transgenic mice with mutations in the pathways controlled by Ptch-1 and p110-alpha, the Hh and PI3K pathways, respectively, coupled with molecular-genetic in-vitro experiments, will be used to observe how these pathways interact to cause breast cancer. Taken together, these studies will provide insight into a novel interaction between two 'druggable' pathways (Hh and PI3K), and how these two pathways cooperate to produce breast cancer.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gjelaj, Ersa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~